8-K
Perspective Therapeutics, Inc. (CATX)
View as plain text
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported): December 01, 2025 |
|---|
Perspective Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
| Delaware | 001-33407 | 41-1458152 |
|---|---|---|
| (State or Other Jurisdiction<br>of Incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |
| c/o Perspective Therapeutics, Inc.<br><br>2401 Elliott Avenue<br><br>Suite 320 | ||
| Seattle, Washington | 98121 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
| Registrant’s Telephone Number, Including Area Code: (206) 676-0900 | ||
| --- |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br>Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.001 par value | CATX | NYSE American LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On December 1, 2025, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
|---|---|
| 99.1 | Corporate Presentation. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PERSPECTIVE THERAPEUTICS, INC. | |||
|---|---|---|---|
| Date: | December 1, 2025 | By: | /s/ Joel Sendek |
| Joel Sendek<br>Chief Financial Officer |
Corporate Presentation
Developing the next generation of targeted therapies
Higher potency payloads with cancer-specific targeting
Upcoming data milestones
Radiopharmaceutical therapy poised to revolutionize oncology treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT
Perspective’s Innovative Platform
Perspective’s radiopharmaceutical platform optimized for a broader therapeutic window
Perspective’s proprietary chelator has been optimized for lead-based RPTs
Proposed mechanism of action for 212Pb
Rationale for synergy with immune checkpoint inhibitors
Supply Chain and Manufacturing Infrastructure
On-demand order fulfillment at regional sites to deliver finished products
Neuroendocrine Tumors: VMT-⍺-NET
Trial design: [212Pb]VMT-⍺-NET Phase 1/2a for PRRT naïve neuroendocrine tumors
Compelling anti-tumor activity
Durable disease control across all doses
Signal of sustained anti-tumor activity
Best-in-class safety profile1
Select adverse events of special interest
Mild and generally transient blood creatinine increase
[212Pb]VMT-α-NET was well-tolerated and demonstrated compelling anti-tumor activity
Melanoma Program: VMT01/02
Trial design: [212Pb]VMT01 Phase 1/2a for metastatic melanoma
Treatment emergent adverse events (all grades, occurring in ≥ 2 patients)
PSV359 is active against FAP-α expression on tumor and on stroma
Trial design: [212Pb]PSV359 Phase 1/2a trial
General Corporate Information
Abbreviations
APPENDIX
NETs trials
Potential for differentiated profile based on molecular design
Durable disease control across all doses
Refractory metastatic melanoma trials
Daily production at regional sites ensures supply of ready-to-administer product
Perspective’s pre-targeting platform